A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 21 Nov 2018 Status changed from planning to not yet recruiting.
- 05 Oct 2018 New trial record